Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of @entity1778 in XXXX .

@entity1 @entity558 @entity146 @entity3052 @entity1778 @entity393 @entity1349
Stringent complete remission (CR) in @entity3052 ( @entity3052 ) requires the absence of both morphologic and flow cytometric evidence of disease. We have previously shown that persistent @entity3052 detected by flow cytometry (FC+) before @entity146 ( @entity146 ) allogeneic hematopoietic cell transplantation (alloHCT) was associated with significantly increased relapse, shorter disease-free survival (DFS), and poorer @entity1349 ( @entity1349 ), independent of morphologic blast count. We evaluated the effect of FC status on outcomes of alloHCT for @entity3052 after either @entity558 ( @entity558 ) or @entity146 regimens in 203 @entity1 ( @entity558 , n  =  80, and @entity146 , n  =  123) with no morphologic evidence of persistent @entity3052 pretransplant on marrow biopsy. The allografts included 130 umbilical cord blood (UCB) and 73 sibling donors. We performed central review of pretransplant standard sensitivity FC to identify detectable FC+. Twenty-five @entity1 were FC+, including 15 (18.7%) receiving @entity558 and 10 (8.1%) @entity146 alloHCT. Among @entity146 @entity1 FC+ was associated with significantly inferior relapse, DFS, and @entity1349 (multiple regression HR, 3.8; 95% CI, 1.7 to 8.7; P  <  .01 for relapse; HR, 2.9; 95% CI, 1.4 to 5.9; P  <  .01 for DFS; and HR, 3.4; 95% CI, 1.7 to 7; P  <  .01 for @entity1349 ). In contrast, FC+ status was not associated with relapse or @entity393 after @entity558 . These data suggest that @entity558 , but not @entity146 , overcomes the negative effect of pretransplant FC+ after sibling or UCB alloHCT. Therefore, a @entity1778 -free state is preferred for those treated with @entity146 .
